LTR Pharma (ASX:LTP) announced that its Phase 1 clinical study of SPONTAN nasal spray has been accepted for podium presentation at the World Meeting on Sexual Medicine 2026, organised by the International Society of Sexual Medicine.
The study, led by Professor Eric Chung, compared the pharmacokinetics and safety of SPONTAN (vardenafil 5 mg) administered intranasally with oral vardenafil tablets (10 mg) in healthy adult males.
Results showed that SPONTAN achieved a faster absorption rate, with a shorter median time to maximum plasma concentration and higher dose-normalised bioavailability, despite a lower administered dose.
Both formulations were well tolerated, with mainly mild and transient adverse events.
The findings suggest that SPONTAN could offer a more rapid onset of action and greater treatment flexibility for patients with erectile dysfunction.
Professor Chung noted that the podium acceptance reflects strong international scientific interest in the intranasal delivery platform and its potential clinical advantages over oral tablets.
The study, sponsored by LTR Pharma and executed by independent investigators, will be presented to the global sexual medicine community at WMSM 2026.